Evidence map›Paper›PMID 41059552›Full record

ArticleMicrobiologyOpen2025

Assessing the in Planta Efficacy of Oxathiapiprolin as a Potential Treatment for Kauri Dieback Disease.

Hannah F Robinson, Jade T T Palmer, Monica L Gerth

Abstract read
In one paragraph

Article in MicrobiologyOpen, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hannah F RobinsonSchool of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.ORCID 0000-0002-4032-892X
Jade T T PalmerSchool of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.ORCID 0009-0001-6779-7638
Monica L GerthSchool of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.ORCID 0000-0002-7959-7852

Funding

Jade Palmer gratefully acknowledges support via a doctoral scholarship co-funded by Tiakina Kauri (part of the Ministry for Primary Industries, New Zealand) and Victoria University of Wellington. Research costs were supported by funding from Ngā Rākau Taketake (part of the BioHeritage National Science Challenge, funded by the New Zealand Ministry of Business, Innovation and Employment (MBIE)) and an MBIE Smart Ideas grant (RTVU2201).
6 · The paper itself

Abstract

Phytophthora agathidicida, a plant pathogenic oomycete, causes fatal dieback disease in New Zealand kauri trees (Agathis australis). Currently, few treatments exist to prevent or cure this infection. Previous research has demonstrated the potent in vitro inhibition of multiple lifecycle stages of P. agathidicida by the oomycide oxathiapiprolin. In this study, we have evaluated the efficacy of oxathiapiprolin in planta as either a protective or curative treatment. Kauri seedlings (1-2 years old) were treated with 10 or 50 mg of oxathiapiprolin, in the form of Zorvec Enicade, per seedling as a soil drench either before (7 days) or after (15 days) inoculation with P. agathidicida NZFS 3770 to test for protective and curative activities, respectively. Results showed that oxathiapiprolin treatments successfully protected the kauri seedlings from disease, with the higher dose (50 mg) demonstrating greater efficacy. However, the treatments did not cure kauri seedlings already infected with P. agathidicida, likely because the infection was already well-established by the time of treatment. This study demonstrates that, while oxathiapiprolin shows protective effects against P. agathidicida infection in kauri seedlings, its lack of curative properties significantly limits its potential as a practical tool for managing kauri dieback disease.

Indexed as

Hydrocarbons, FluorinatedPhytophthoraPlant DiseasesPyrazolesNew ZealandSeedlingsHydrocarbons, FluorinatedoxathiapiprolinPyrazolesdisease managementin planta efficacyprotective treatmentZorvec

Identifiers

PMID41059552
PMCPMC12505020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.